| 张惠丽,仲宁,杨庆蕊,马琳.房颤患者PCI术后华法林的合理使用与药学监护[J].中国药事,2020,34(10):1225-1230 |
| 房颤患者PCI术后华法林的合理使用与药学监护 |
| Rational Use and Pharmaceutical Care of Warfarin in Patients with Atrial Fibrillation After PCI |
| |
| DOI：10.16153/j.1002-7777.2020.10.016 |
| 中文关键词: 房颤PCI术后 华法林 药学监护 |
| 英文关键词: Atrial Fibrillation after PCI warfarin pharmacological care |
| 基金项目:新乡市科技攻关项目(编号 CXGG17039) |
|
| 摘要点击次数: 728 |
| 全文下载次数: 215 |
| 中文摘要: |
| 目的：探索房颤患者PCI术后华法林的合理使用与药学监护。方法：结合房颤PCI术后最新临床数据特征和华法林防治指南、合理用药专家共识、文献资料以及临床药师工作经验，制定药学监护工作模式。从患者因素、药物因素、药物检测、相互作用、不良反应监测等方面进行分析。结果与结论：房颤PCI术后患者药物治疗较为棘手，因此，及时进行房颤患者风险评估和防治，实施个体化给药治疗， 提供实时的药学监护是十分必要的。 |
| 英文摘要: |
| Objective: To explore the rational use and pharmaceutical care of warfarin in patients with Atrial Fibrillation after PCI. Methods: Based on the latest clinical data of Atrial Fibrillation after PCI, the guidelines to warfarin prevention and treatment, consensus of rational drug use experts, the literature and clinical pharmacists' work experience, the working mode of pharmaceutical care was developed. Analysis was carried out from the aspects of patients, drugs, drug detection, interaction and adverse reaction monitoring, etc. Results and Conclusion: The drug treatment of Atrial Fibrillation after PCI is relatively difficult, so it is very necessary to timely carry out risk assessment and prevention for patients with Atrial Fibrillation, implement individualized drug administration and provide real-time pharmaceutical care to them. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|